(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
U.S. overhauls childhood vaccine schedule, recommends fewer shots - 2Verdicts against social media companies carry consequences. But questions linger
- 3'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- 4The Best Internet Mastering Stages for Expertise Improvement
- 5Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- When a sperm whale gives birth, the mother gets help from her friends
- The Main 20 Photography Instagram Records to Follow
- Staggering Spots to Stargaze All over the Planet
- The Development of Shipping: Controlling Towards a More Associated Future
- Make your choice for the sweet that transports you to its nation of beginning!
- Must-Have Cooking Machine in Your Kitchen
- Nations for Rock Climbing
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Our 10 favorite Space.com reader astronomy photos of 2025
